Non-Hodgkin's Lymphoma T Cell Protocol
OBJECTIVES: I. Determine whether event-free survival for children with T-cell non-Hodgkin's
lymphoma (NHL) can be improved by the addition of a third intensification block at 35 weeks.
II. Determine biology and treatment response of T-cell NHL and T-cell acute lymphocytic
leukemia when both are treated with an identical leukemia type protocol and receive a third
intensification block. III. Improve the outcome for the 25% of children who are not in
remission at eight weeks by the addition of a block of sustained intensification before high
dose methotrexate and continuing treatment.
OUTLINE: Patients receive induction therapy on days 1-28. Patients receive supportive oral
prednisolone daily for three doses during weeks 1-4, vincristine IV weekly for 5 weeks
starting on day 1, asparaginase intramuscularly or subcutaneously three times a week
beginning on day 4, and methotrexate intrathecally on days 1 and 8. Patients who meet
certain criteria are given first intensification therapy beginning on day 29. Patients
receive three doses of oral prednisolone, vincristine IV on day 1, daunorubicin IV over 6
hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, cytarabine IV every 12 hours
by bolus injection on days 1-5, oral thioguanine daily on days 1-5, and methotrexate
intrathecally as in induction therapy. Patients are followed at 8 weeks. Those patients who
experience remission receive a third intensification block at 35 weeks. All patients receive
three methotrexate infusions followed by continuation therapy beginning at week 14. As
continuation therapy, patients receive oral mercaptopurine daily, oral methotrexate weekly,
vincristine IV every 4 weeks, oral prednisolone for 5 days every 4 weeks, and intrathecal
methotrexate every 12 weeks beginning at week 23 until 100 weeks from the start of
treatment. Continuation therapy will be interrupted at about week 20 for the second
intensification therapy. For second intensification therapy, patients receive oral
prednisolone daily for 5 days, a single dose of vincristine on day 1, daunorubicin IV over 6
hours on days 1 and 2, etoposide IV over 4 hours on days 1-5, bolus injections of cytarabine
every 12 hours on days 1-5, oral thioguanine daily on days 1-5, and intrathecal methotrexate
as in induction therapy. Continuation therapy re-starts at week 23. Patients who receive the
third intensification therapy will begin at week 35. For the third intensification therapy,
patients receive three doses of oral dexamethasone, IV vincristine on day 1 of weeks 35-38,
subcutaneous asparaginase for 9 days during weeks 35-38, intrathecal methotrexate on day 1
of weeks 35 and 39, IV cyclophosphamide on day 1 of weeks 39 and 41, subcutaneous or IV
cytarabine daily on days 1-4 of weeks 39- 42, and oral thioguanine daily during weeks 39-42.
Continuation therapy re-starts at week 42/43. Some patients may receive radiotherapy during
chemotherapy. Patients are followed every month for 1 year, every 2 months for the next
year, every 6 months for the next 3 years, then annually thereafter.
PROJECTED ACCRUAL: Approximately 100 patients will be accrued for this study within 5 years.
Primary Purpose: Treatment
Judith M. Chessells, MD
Institute of Child Health
United States: Federal Government